AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to <i>Aedes</i> Mosquito Bites in Humans.

ABSTRACT:

Background

The global health burden of mosquito-borne viruses, including dengue, yellow fever, Zika, and chikungunya, is rising due to climate change and globalisation, which favour mosquito habitat expansion. The genetic diversity of these viruses complicates the development of virus-specific vaccines or antivirals, highlighting the need for pan-viral strategies. As the common vector for these pathogens, mosquitoes and specifically their salivary proteins represent a promising target for such interventions. Mosquito saliva, secreted into the skin during biting, has immunomodulatory effects that can enhance host susceptibility to infection, but these mechanisms are not well defined in humans.

Methods

The objective of this study was to determine whether AGS-v PLUS, a vaccine

SUBMITTER: Barningham L 

PROVIDER: S-EPMC12567680 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature